- Home
- AYTU vs RDHL Comparison
AYTU vs RDHL Comparison
Compare AYTU & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AYTU | RDHL |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 3.3M |
| IPO Year | 2015 | 2012 |
Fundamental Metrics
Financial Performance| Metric | AYTU | RDHL |
|---|---|---|
| Price | $2.13 | $0.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.50 | N/A |
| AVG Volume (30 Days) | 40.5K | ★ 209.2K |
| Earning Date | 09-22-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,632,080.00 | N/A |
| Revenue This Year | $17.96 | $17,592.31 |
| Revenue Next Year | $27.98 | $25.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 277.47 | N/A |
| 52 Week Low | $1.80 | $0.48 |
| 52 Week High | $3.07 | $2.26 |
Technical Indicators
Market Signals| Indicator | AYTU | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 34.08 |
| Support Level | $2.05 | N/A |
| Resistance Level | $2.36 | $1.07 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 48.98 | 12.97 |
Price Performance
Historical ComparisonAbout AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.